RxDoctor Payments Data

Darrel Stout, MD

Family Medicine · Edmond, OKNPI 1356362073

Payments from drug & device makers

$12,905in general payments, 2019–2025

Across 1,044 payments — averaging $12.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • Boehringer Ingelheim$1K
  • GSK$920
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$12,75199%
  • Education$1551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)159$1,769
Novo Nordisk136$1,499
AstraZeneca45$1,282
Pfizer139$1,240
Boehringer Ingelheim81$1,010
GSK103$920
Lilly USA, LLC62$674
Amgen(2 entities)34$521
Takeda Pharmaceuticals U.S.A., Inc.26$419
Merck39$381
Amarin Pharma, Inc.27$302
Supernus Pharmaceuticals, Inc.29$288
Sanofi-aventis U.S. LLC17$241
Abbott10$191
Bayer12$176
Astellas Pharma US Inc10$171
Dexcom, Inc.8$124
Johnson & Johnson8$116
Novartis8$114
Ironwood Pharmaceuticals, Inc8$112
Teva Pharmaceuticals USA, Inc.6$94
Eisai Inc.4$77
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$74
Genentech USA, Inc.4$70
Otsuka America Pharmaceutical, Inc.4$69
Kaleo, Inc.4$67
Biohaven Pharmaceuticals, Inc.4$57
Ultragenyx Pharmaceutical Inc.3$50
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$48
Almatica Pharma LLC3$47
Lundbeck LLC2$45
Nabriva Therapeutics, PLC3$41
Ironshore Pharmaceuticals Inc.3$36
Nestle Healthcare Nutrition Inc.2$34
Shire North American Group Inc2$34
E.r. Squibb & Sons, L.L.C.2$33
Shield Therapeutics Inc1$33
Scynexis, Inc.2$32
Sunovion Pharmaceuticals Inc.2$32
Idorsia Pharmaceuticals US Inc2$29
Kyowa Kirin, Inc.2$28
Upsher-smith Laboratories LLC2$27
Madrigal Pharmaceuticals1$27
Mayne Pharma Commercial LLC1$23
Jazz Pharmaceuticals Inc.2$23
Xeris Pharmaceuticals, Inc.1$21
Edwards Lifesciences1$21
Cranial Technologies, Inc1$20
Sanofi Pasteur Inc.1$16
Neos Therapeutics, LP1$16
Biogen1$15
Paratek Pharmaceuticals, Inc.1$15
Biohaven Pharmaceutical Holding Company Ltd.1$14
Antares Pharma, Inc.1$13
Esperion Therapeutics, Inc.1$13
Aytu Biopharma, Inc.1$13
Dynavax Technologies Corporation1$12
Nalpropion Pharmaceuticals LLC1$12
Kowa Pharmaceuticals America, Inc.1$11
Bristol Myers Squibb1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,905 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$134,135
Medicare patients
501
Services billed
4,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$95,168
MounjaroTirzepatide50$87,787
EliquisApixaban50$66,554
JardianceEmpagliflozin47$64,579
JanuviaSitagliptin Phosphate49$53,000
RybelsusSemaglutide22$31,914
LinzessLinaclotide25$29,228
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$27,289
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$22,356
FarxigaDapagliflozin Propanediol15$21,998
JanumetSitagliptin Phos/Metformin Hcl18$19,560
MyrbetriqMirabegron27$16,190
Janumet XrSitagliptin Phos/Metformin Hcl11$15,286
Tresiba Flextouch U-200Insulin Degludec18$14,121
XareltoRivaroxaban15$12,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,499$127,08288 claims
MerckJanuvia, Janumet, Janumet Xr, Dulera$381$100,57394 claims
Lilly USA, LLCMounjaro$674$87,78750 claims
PfizerEliquis, Premarin$1,240$76,81173 claims
Boehringer IngelheimJardiance, Spiriva Respimat$1,010$75,74760 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$920$40,31055 claims
AbbVieLinzess, Synthroid$1,769$32,06476 claims
AstraZenecaFarxiga$1,282$21,99815 claims
Astellas Pharma US IncMyrbetriq$171$16,19027 claims
Johnson & JohnsonXarelto$116$12,87815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →